Crossmark

Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment of Slovenian patients undergoing kidney transplantation in the U-PGx PREPARE study

Crossref DOI link: https://doi.org/10.1038/s41397-025-00365-2

Published Online: 2025-03-10

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fragoulakis, Vasileios

Koufaki, Margarita-Ioanna

Mlinšek, Gregor

Blagus, Tanja

Klen, Jasna

Patrinos, George P. https://orcid.org/0000-0002-0519-7776
Dolžan, Vita

Mitropoulou, Christina https://orcid.org/0000-0002-9184-4668
Funding

Funding for this research was provided by:

European Commission
License Information

Text and Data Mining valid from 2025-03-10

Version of Record valid from 2025-03-10
More Information

Article History

Received: 21 April 2024

Revised: 23 January 2025

Accepted: 24 February 2025

First Online: 10 March 2025

Ethics approval

: The study was approved by the National Medical Ethics Committee of the Republic of Slovenia (0120-591/2016; KME 44/12/16).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below